GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Solid Biosciences Inc (NAS:SLDB) » Definitions » Cash Flow for Lease Financing

SLDB (Solid Biosciences) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Solid Biosciences Cash Flow for Lease Financing?

Solid Biosciences's Cash Flow for Lease Financing for the three months ended in Mar. 2025 was $0.00 Mil. Solid Biosciences's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Dec. 2024 ), Solid Biosciences's Cash Flow for Lease Financing remained the same in Mar. 2025 ($0.00 Mil).


Solid Biosciences Cash Flow for Lease Financing Historical Data

The historical data trend for Solid Biosciences's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solid Biosciences Cash Flow for Lease Financing Chart

Solid Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Solid Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Solid Biosciences Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solid Biosciences Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Solid Biosciences's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Solid Biosciences Business Description

Traded in Other Exchanges
N/A
Address
500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Executives
Clare Kahn director 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Bain Capital Life Sciences Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Gabriel Brooks officer: Chief Medical Officer C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
David T Howton officer: See Remarks VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Paul Herzich officer: Chief Technology Officer 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Jessie Hanrahan officer: Chief Regulatory Officer 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Kevin Tan officer: CFO & Treasurer 20 HICKORY ROAD, WELLESLEY MA 02482
Ilan Ganot director, officer: Chief Executive Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Alexander Cumbo director, officer: President and CEO 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jennifer Marlowe officer: CSO, FA & Cardiac 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Carl Ashley Morris officer: Chief Scientific Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Georgia Keresty director C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Perceptive Venture Advisors, Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003